Rocket Pharmaceuticals (RCKT) Expected to Announce Quarterly Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Rocket Pharmaceuticals to post earnings of ($0.42) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals Stock Performance

RCKT opened at $3.45 on Thursday. The company has a quick ratio of 7.30, a current ratio of 7.30 and a debt-to-equity ratio of 0.06. The firm has a market cap of $373.36 million, a PE ratio of -1.53 and a beta of 0.48. The business has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $3.39. Rocket Pharmaceuticals has a fifty-two week low of $2.19 and a fifty-two week high of $11.09.

Insider Activity at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 12,279 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the transaction, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at approximately $3,482,268.95. This represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the sale, the general counsel directly owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 28,258 shares of company stock worth $93,534. Company insiders own 24.76% of the company’s stock.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter valued at approximately $25,000. CANADA LIFE ASSURANCE Co raised its position in Rocket Pharmaceuticals by 94.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 5,926 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at approximately $38,000. Virtu Financial LLC bought a new stake in Rocket Pharmaceuticals in the third quarter worth approximately $40,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals during the 3rd quarter worth $43,000. 98.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RCKT has been the subject of a number of recent analyst reports. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a research report on Friday, December 19th. Morgan Stanley set a $5.00 target price on shares of Rocket Pharmaceuticals in a report on Thursday, January 8th. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. Bank of America decreased their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. downgraded shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, November 18th. Eight equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Rocket Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.36.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.